Madrigal Pharmaceuticals - by Joshua Elkington
Axial: https://linktr.ee/axialxyz
Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio, Seranova Bio, Delix Therapeutics, Simcha Therapeutics, among others often when they are no more than an idea. We are fanatical about helping the rare inventor who is compelled to build their own enduring business. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company. We are excited to be in business with you - email us at info@axialvc.com
Madrigal reported transformative clinical data for NASH with their lead, resmetirom, targeting a thyroid hormone pathway. With no approved medicines, NASH is one of the biggest problems in healthcare & Madrigal has gone farther than any company in the space.
Founded in 2011, by a husband-wife duo, Paul Friedman (former CEO of Incyte) & Rebecca Taub (worked at Roche previously & discovered resmetirom while there), Madrigal licensed their lead from Roche after the biopharma shifted away from metabolic diseases.
In late-2022, Madrigal reported phase 3 (N=955) data in non-cirrhotic Nash with moderate-to-advanced fibrosis, meeting both co-primary endpoints. NASH = non-alcoholic steatohepatitis and affects 3%-5% of all adults in the US https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3
Learn more about Madrigal here:
https://www.madrigalpharma.com/
ncG1vNJzZmiZqJ6urXrSrpmsrJGYuG%2BvzqZmqWedlrGztcaao2aomJa%2Frq3CnqytoZOWubQ%3D